Grandfield & Dodd’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$620K Sell
3,144
-68
-2% -$13.1K 0.04% 132
2025
Q4
$591K Buy
3,212
+23
+0.7% +$4.03K 0.03% 132
2025
Q3
$489K Buy
3,189
+32
+1% +$4.84K 0.03% 140
2025
Q2
$441K Sell
3,157
-95
-3% -$13.3K 0.03% 144
2025
Q1
$478K Sell
3,252
-1
-0% -$145 0.03% 141
2024
Q4
$426K Sell
3,253
-460
-12% -$64.4K 0.03% 150
2024
Q3
$579K Sell
3,713
-728
-16% -$118K 0.03% 134
2024
Q2
$693K Sell
4,441
-165
-4% -$24.8K 0.04% 120
2024
Q1
$624K Sell
4,606
-285
-6% -$37.7K 0.04% 126
2023
Q4
$659K Sell
4,891
-528
-10% -$68.6K 0.05% 124
2023
Q3
$734K Sell
5,419
-434
-7% -$59.3K 0.05% 119
2023
Q2
$838K Sell
5,853
-385
-6% -$56.6K 0.06% 111
2023
Q1
$866K Sell
6,238
-94
-1% -$12.6K 0.06% 112
2022
Q4
$859K Sell
6,332
-1
-0% -$125 0.06% 110
2022
Q3
$690K Sell
6,333
-246
-4% -$31.2K 0.06% 115
2022
Q2
$870K Hold
6,579
0.07% 106
2022
Q1
$870K Sell
6,579
-200
-3% -$24K 0.06% 114
2021
Q4
$790K Sell
6,779
-356
-5% -$41.9K 0.05% 116
2021
Q3
$860K Buy
+7,135
New +$831K 0.06% 109

Other funds holding AZN

Grandfield & Dodd's AZN Position: Q1 2026 in Review

Grandfield & Dodd reduced its AstraZeneca (AZN) stake by 2.1% in Q1 2026, selling an estimated $13.1K and leaving 3,144 shares worth $620K. The position accounts for 0.04% of the portfolio, ranked #132.

Grandfield & Dodd first reported a position in AZN in Q3 2021 and has held it in 19 quarters since. The position peaked at $870K in Q2 2022. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Grandfield & Dodd held 3,144 shares of AstraZeneca worth $620K as of Q1 2026.
  • Grandfield & Dodd sold 68 AstraZeneca shares in Q1 2026, an estimated $13.1K.
  • AstraZeneca made up 0.04% of Grandfield & Dodd's portfolio in Q1 2026, its #132 holding.
  • Grandfield & Dodd first reported a position in AstraZeneca in Q3 2021 and has held it in 19 quarters since.
  • Grandfield & Dodd's AstraZeneca position peaked at $870K in Q2 2022.
  • 1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.